Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2001

View Archived Issues

VEGF receptor tyrosine kinase inhibitor blocks proliferation, migration of multiple myeloma cells

ASH news: PD-180970 blocks activation of Stat5 and inhibits CML cell growth

Oral HDAC inhibitor MS-275 induces cell cycle arrest, apoptosis and differentiation in AML cells

Clinical efficacy and safety of zosuquidar as a modulator of P-glycoprotein in leukemia and lymphoma

OSI R&D progress highlighted at inaugural research day

Studies at Dana-Farber point to usefulness of beta-lapachone in multiple myeloma

Clinical trials of milnacipran in FMS expected to begin in 2002

Medivir designates candidate drug in HIV/NNRTI research program

Telomerase inhibitor collaboration established by Geron and Ribozyme

Encouraging results reported from phase IIa trial of XTL-001 in chronic hepatitis B patients

GSK and Roche to codevelop and copromote ibandronate

PDL's humanized Zamyl MAb safe and active in refractory/relapsed AML

FDA advisory committee recommends Gliadel Wafer for newly diagnosed malignant glioma

Arixtra receives FDA approval

Phase II trial of Avicine cancer vaccine shows survival benefit

Hexvix cleared for phase III trials in the U.S.

Millennium and Cor Therapeutics announce merger plans

Clofarex designated an orphan drug for leukemia; encouraging clinical findings reported

Novel macrocyclic peptidomimetic antitumor agents in development at U. of Pennsylvania

Trio of pharmaceutical companies jointly design potential agents for bone disorders

Novel compounds for lipid disorders emerge from R&D at Novartis

DuPont researchers identify lactam inhibitors of Abeta production

U.S. academic researchers claim bile acid-containing prodrugs

Preparation and use of CXCR2 receptor modulators disclosed by AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...